Literature DB >> 20938038

Protective effect of L-arginine in experimentally induced myocardial ischemia: comparison with aspirin.

Alaaeldin I Saleh1, Sahar M Abdel Maksoud, Shohda A El-Maraghy, Mohamed Z Gad.   

Abstract

OBJECTIVE: Coronary artery diseases including myocardial ischemia (MI) remain one of the leading causes of death worldwide. This study was designed to compare the protective effect of L-arginine versus aspirin from the biochemical changes associated with MI injury. EXPERIMENTAL
DESIGN: Four groups of male New Zealand white rabbits were investigated. Normal group (n = 8) rabbits were fed standard chow pellets, untreated MI group (n = 16), where hypercholesterolemia was induced by feeding the animals with a diet containing 2% cholesterol for 28 days, L-arginine group (n = 12) rabbits were fed a 2% cholesterol-enriched diet in conjunction with L-arginine (2.25 g %) in drinking water for 28 days, and aspirin group (n = 12) rabbits were fed 2% cholesterol-enriched diet in conjunction with aspirin administered orally (0.7 mg/kg per d) for 28 days. After 28 days, MI was induced in all groups, except the normal group, by a single subcutaneous (sc) injection of isoproterenol hydrochloride (0.2 mg/kg body weight [bw]). Animals were sacrificed 6 hours later.
RESULTS: Our results showed that L-arginine was more effective than aspirin in reducing platelet aggregation, reducing low-density lipoprotein (LDL) oxidizability, preventing aortic intimal thickening, and maintaining histological architecture of the myocardium. Both drugs, however, had similar positive effects on plasma fibrinogen levels and on the prevention of myocardial release of cardiac troponin I and creatine kinase-MB. The effect on hypercholesterolemia was insignificant for both drugs. Aspirin was more effective than L-arginine in prolonging prothrombin time.
CONCLUSION: L-arginine supplementation represents a potentially novel nutritional strategy for preventing and treating coronary artery diseases especially in cases of aspirin resistance and/or hypersensitivity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20938038     DOI: 10.1177/1074248410378506

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  4 in total

1.  Effect of L-arginine supplementation on insulin resistance and serum adiponectin concentration in rats with fat diet.

Authors:  Anna Miczke; Joanna Suliburska; Danuta Pupek-Musialik; Lucyna Ostrowska; Anna Jabłecka; Zbigniew Krejpcio; Damian Skrypnik; Paweł Bogdański
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Changes in the Plasma and Platelet Nitric Oxide Biotransformation Metabolites during Ischemic Stroke-A Dynamic Human LC/MS Metabolomic Study.

Authors:  Maciej Bladowski; Ewa Szahidewicz-Krupska; Jerzy Wiśniewski; Paulina Fortuna; Justyna Chojdak-Łukasiewicz; Slawomir Budrewicz; Mariusz Fleszar; Adrian Doroszko
Journal:  Antioxidants (Basel)       Date:  2022-05-12

3.  Novel metabolic roles of L-arginine in body energy metabolism and possible clinical applications.

Authors:  K Hristina; T Langerholc; M Trapecar
Journal:  J Nutr Health Aging       Date:  2014       Impact factor: 4.075

4.  Origanum majorana L. Extract Protects Against Isoproterenol-Induced Cardiotoxicity in Rats.

Authors:  Abeer M Rababa'h; Miya A Alzoubi
Journal:  Cardiovasc Toxicol       Date:  2021-03-30       Impact factor: 3.231

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.